IL147123A0 - Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies - Google Patents

Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies

Info

Publication number
IL147123A0
IL147123A0 IL14712300A IL14712300A IL147123A0 IL 147123 A0 IL147123 A0 IL 147123A0 IL 14712300 A IL14712300 A IL 14712300A IL 14712300 A IL14712300 A IL 14712300A IL 147123 A0 IL147123 A0 IL 147123A0
Authority
IL
Israel
Prior art keywords
hla
soluble forms
treating inflammatory
compositions containing
inflammatory skin
Prior art date
Application number
IL14712300A
Other languages
English (en)
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Publication of IL147123A0 publication Critical patent/IL147123A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14712300A 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies IL147123A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
PCT/FR2000/001670 WO2000078337A1 (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Publications (1)

Publication Number Publication Date
IL147123A0 true IL147123A0 (en) 2002-08-14

Family

ID=9546968

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14712300A IL147123A0 (en) 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
IL147123A IL147123A (en) 1999-06-18 2001-12-16 Use of compositions containing at least one soluble form of G – HLA for the preparation of a medicinal product for the treatment of inflammatory pathologies of the skin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL147123A IL147123A (en) 1999-06-18 2001-12-16 Use of compositions containing at least one soluble form of G – HLA for the preparation of a medicinal product for the treatment of inflammatory pathologies of the skin

Country Status (10)

Country Link
EP (1) EP1189627B1 (de)
JP (1) JP2003508351A (de)
AT (1) ATE251911T1 (de)
CA (1) CA2377519C (de)
DE (1) DE60005952T8 (de)
DK (1) DK1189627T3 (de)
ES (1) ES2206286T3 (de)
FR (1) FR2794977B1 (de)
IL (2) IL147123A0 (de)
WO (1) WO2000078337A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
WO2007011044A1 (ja) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
WO2008058913A1 (de) 2006-11-15 2008-05-22 Basf Se Verfahren zur herstellung von polyurethan-weichschaumstoffen
EP2184070A1 (de) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Proteine und pharmazeutische Verwendungen davon
EP2184297A1 (de) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Polypeptide und pharmazeutische Verwendungen davon
EP2264067A1 (de) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 Multimere und pharmazeutische Verwendung davon
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
EP2575881B1 (de) * 2010-05-28 2016-09-14 INSERM - Institut National de la Santé et de la Recherche Médicale Spezifische anti-cd160-antikörper zur behandlung von augenerkrankungen auf grundlage von neoangiogenese
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
AU2020307667A1 (en) 2019-06-27 2022-01-20 Crispr Therapeutics Ag Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
EP3994278A1 (de) * 2019-07-05 2022-05-11 Intellexon GmbH Hla-h in der medizin und diagnostik
EP4171585A1 (de) 2020-06-26 2023-05-03 CRISPR Therapeutics AG Allogene zelltherapie von b-zell-malignomen mit genetisch manipulierten, auf cd19 abzielenden t-zellen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
EP0819171A1 (de) * 1995-04-07 1998-01-21 The Regents Of The University Of California Antikörper zum nachweis von hla-g
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
FR2760023B1 (fr) * 1997-02-21 2004-05-07 Commissariat Energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications

Also Published As

Publication number Publication date
ES2206286T3 (es) 2004-05-16
ATE251911T1 (de) 2003-11-15
FR2794977A1 (fr) 2000-12-22
CA2377519A1 (fr) 2000-12-28
DE60005952D1 (de) 2003-11-20
EP1189627B1 (de) 2003-10-15
FR2794977B1 (fr) 2003-10-31
IL147123A (en) 2010-06-30
DE60005952T2 (de) 2004-07-29
CA2377519C (fr) 2011-09-27
WO2000078337A1 (fr) 2000-12-28
DE60005952T8 (de) 2004-11-04
DK1189627T3 (da) 2004-02-16
JP2003508351A (ja) 2003-03-04
EP1189627A1 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
IL127581A0 (en) Crystal form i of clarithromycin
IL145470A0 (en) Compositions for the treatment of immune diseases
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
MY133996A (en) Compounds for the treatment of ischemia
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ZA982968B (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP1110908A4 (de) Verfahren zur herstellung von hydroxyapatit und hydroxyapatitkomplexe und deren herstellung
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
GB9907571D0 (en) Compounds
GB2357036B (en) Process for the preparation of dental prosthesis
MY120237A (en) Method for the synthesis of quinoline derivatives
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
HUP0200825A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases
IL120005A (en) Pharmaceutical compositions for the treatment of the eye
HUP0104928A3 (en) Pharmaceutical compositions comprising micronised colistin sulphomethate natrium, process for their preparation and their use
PL350327A1 (en) Compositions for the treatment of skin diseases
AU7079300A (en) Compositions and methods for the treatment of immune related diseases